Savara, Inc. (NASDAQ: SVRA)

This lawsuit is for anyone who acquired securities in Savara, Inc. (NASDAQ: SVRA) from March 7, 2024 through May 23, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the FDA was likely to approve the Company’s Biologics License Application for its drug, MOLBREEVI, despite knowing that the Company submitted to the FDA an incomplete application.

On May 27, 2025, Savara issued a press release announcing that the U.S. Food and Drug Administration had issued a refusal-to-file letter for the Company’s Biologics License Application for MOLBREEVI, determining that the submission was not sufficiently complete and requesting additional Chemistry, Manufacturing, and Controls data. That same day, Guggenheim published a report lowering its price target for Savara and warning of potential delays in commercialization and the likelihood of additional capital raises. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Savara, Inc. (NASDAQ: SVRA) from March 7, 2024 through May 23, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.